Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC)

Completed

• Conditions: Peritoneal Mesotheliomas
• Interventions: Procedure: Cytoreductive surgery and HIPEC

• Registration Number: NCT01812148
• Lead Sponsor: Maisonneuve-Rosemont Hospital

Brief Summary

Review of the investigators hospital experience in cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) for peritoneal mesotheliomas, using Oxaliplatin as intraperitoneal chemotherapeutic agent.

Detailed Description

Observation of primary outcome:

* Overall Survival

* Disease-free survival

Influencing factors that will be observe:

* Sex

* Blood loss

* Time of surgery

* Number of resection and anastomosis

* Peritoneal Index (PI score)

* Cytoreductibility (CCR score)

Study Timeline

• Study Start: 2012-01
• Status Verified: 2013-03
• Primary Completion: 2013-03
• Study Completion: 2013-03
• Study First Submitted: 2013-03-12
• Study First Submitted QC: 2013-03-15
• Last Update Submitted: 2013-03-15
• Study First Posted: 2013-03-18
• Last Update Posted: 2013-03-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 19

Inclusion Criteria

• Peritoneal mesothelioma

Exclusion Criteria

• Non resectable disease

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Peritoneal Mesotheliomas	Cytoreductive surgery and HIPEC	Cytoreductive surgery and HIPEC

Primary Outcome Measures

Name	Time	Method
Overall survival	5 years

Secondary Outcome Measures

Name	Time	Method
Disease-Free survival	5 years

Trial Locations

Locations (1)

Maisonneuve Rosemont Hospital; 🇨🇦 Montréal, Quebec, Canada